breast cancer

envie a um amigo share this

Research needs in breast cancer

Authors and Affiliations:

Cardoso F1, Harbeck N2, Barrios CH3, Bergh J4, Cortés J5,6, El Saghir N7, Francis PA8, Hudis CA9, Ohno S10, Partridge AH11, Sledge GW12, Smith IE13, Gelmon KA14.

 

1Breast Unit, Champalimaud Clinical Centre, Lisbon, Portugal.

2Breast Center, Department of Obstetrics and Gynaecology, University of Munich (LMU), Munich, Germany.

Research needs in breast cancer

Autores e Afiliações:

Cardoso F1, Harbeck N2, Barrios CH3, Bergh J4, Cortés J5,6, El Saghir N7, Francis PA8, Hudis CA9, Ohno S10, Partridge AH11, Sledge GW12, Smith IE13, Gelmon KA14.

 

1Breast Unit, Champalimaud Clinical Centre, Lisbon, Portugal.

2Breast Center, Department of Obstetrics and Gynaecology, University of Munich (LMU), Munich, Germany.

Total tumor load assessed by one-step nucleic acid amplification assay as an intraoperative predictor for non-sentinel lymph node metastasis in breast cancer

Authors and Affiliations:

Celso Nabais a, Joana Figueiredo a, Paulina Lopes a, Manuela Martins b, António Araújo a

a Department of Surgery, Centro Hospitalar Lisboa Central, Portugal

b Department of Pathology, Centro Hospitalar Lisboa Central, Portugal

 

Abstract:

Precision Cancer Diagnostics: Tracking Genomic Evolution in Clinical Trials

Francisco Beça: Department of Pathology and Cancer Research Institute, Beth Israel Deaconess Cancer Center, Boston, Massachusetts, United States of America, Harvard Medical School, Boston, Massachusetts, United States of America

Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer?

Authrs and Affiliations:

Sofia Braga, Joana Cardoso, Saudade André, Margarida Brito, Pedro Sanchez, Lurdes Orvalho, Lucília Salgado, Sérgio Dias, José B. Pereira-Leal and José Luís Passos-Coelho

 

Jose de Mello Saude, Lisboa, Portugal.

 

Abstract:

Background: The antiangiogenic drug sunitinib has never been evaluated as single agent in untreated breast cancer patients.

3rdWorld Congress on Controversies in Breast Cancer (CoBrCa)

Toranomon Hills, Minatoku, Tokyo, Japan

 

26-28 October, 2017

 

See more informations here: http://cobrca.org/

 

 

Precision Cancer Diagnostics: Tracking Genomic Evolution in Clinical Trials

Numa edição especial intitulada «Translating the Cancer Genome — Implications for Diagnosis and Treatment», da conceituada revista PLoS Medicine, o médico e investigador português Francisco Beça, juntamente com Andrew Beck, discutem um artigo da equipa liderada por Charles Swanton e partilham as suas perspetivas sobre o estado atual da Precision Medicine com especial foco no cancro da mama.

Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer?

Autores e Afiliações:

Sofia Braga, Joana Cardoso, Saudade André, Margarida Brito, Pedro Sanchez, Lurdes Orvalho, Lucília Salgado, Sérgio Dias, José B. Pereira-Leal and José Luís Passos-Coelho

 

Jose de Mello Saude, Lisboa, Portugal.

 

Abstract:

Background: The antiangiogenic drug sunitinib has never been evaluated as single agent in untreated breast cancer patients.

3rdWorld Congress on Controversies in Breast Cancer (CoBrCa)

Toranomon Hills, Minatoku, Tokyo, Japan

 

26-28 October, 2017

 

See more informations here: http://cobrca.org/

 

 

7th Innovation in Breast Cancer symposium

Auditorio Rafael del Pino, Madrid, Spain

 

17-18 February, 2017

 

See more informations here: http://www.doctaforum.net/eventos/innovationinbreastcancer/index.asp?idEvento=2712&idSeccion=946